University of Chieti Pescara
Chieti, Italy
Time filter
Source Type

Agency: European Commission | Branch: H2020 | Program: RIA | Phase: REV-INEQUAL-07-2016 | Award Amount: 5.00M | Year: 2017

IMAJINE aims to formulate new integrative policy mechanisms to enable European, national and regional government agencies to more effectively address territorial inequalities within the European Union. It responds to evidence that spatial inequalities within the EU are increasing, contrary to the principle of territorial cohesion embedded as a third dimension of the European Social Model in the Treaty of Lisbon, and is particularly timely in examining the geographically differentiated impacts of the post-2008 economic crisis and the adoption of austerity policies. IMAJINE uniquely proposes to address the problem of territorial inequalities through an inter-disciplinary and multi-scalar approach that integrates perspectives from economics, human geography, political science and sociology and combines macro-scale econometric analysis and the generation and analysis of new quantitative survey data with regionally-focused qualitative empirical case study research in 11 EU member states; delivered by a multi-disciplinary and multi-national consortium. As such the research builds on the conceptual and methodological state of the art in several disciplines and advances conceptual understanding and the empirical knowledge base by producing new primary data, applying new analytical tests to secondary data and integrating the results along with insights from relational geographical theory and the concept of spatial justice. In particular, the centrality of spatial justice emphasizes the political as well as economic dimensions of territorial inequalities, and IMAJINE will move beyond existing knowledge by considering relationships between measured and perceived inequalities, models of multi-level policy-making and public service delivery, and support for territorial autonomy movements. IMAJINE will further translate these scientific insights into policy applications through participatory scenario building exercises with governance and civil society stakeholders.

Agency: European Commission | Branch: H2020 | Program: ECSEL-RIA | Phase: ECSEL-04-2015 | Award Amount: 18.33M | Year: 2016

The ageing population and related increase in chronic diseases put considerable pressure on both the healthcare system and the society, resulting in an unsustainable rise of healthcare costs. As a result there is an urgent need to improve efficiency of care and reduce hospitalisation time in order to control cost and increase quality of life. Addressing this need, medical applications need to become less invasive and improve disease detection, diagnosis and treatment using advanced imaging and sensing techniques. ASTONISH will deliver breakthrough imaging and sensing technologies for monitoring, diagnosis and treatment applications by developing smart optical imaging technology that extends the use of minimally invasive diagnosis and treatment and allows for unobtrusive health monitoring. The project will integrate miniaturized optical components, data processing units and SW applications into smart imaging systems that are less obtrusive, cheaper, more reliable and easier to use than state of the art systems. This results into 6 demonstrators by which the technologies will be validated and which allow for pre-clinical testing in the scope of the project. The overall concept within ASTONISH builds on the development and application of common imaging/sensing technologies. Smart algorithms, multimodal fusion techniques and biomedical signal processing will process the acquired data and advanced user interfaces will simplify the complex clinical tasks. These technology components will be integrated to build application specific solutions for physiological signs monitoring, tumour detection, minimally invasive surgery, brain function monitoring and rehabilitation. The ASTONISH partners cover the full value chain, from semiconductor manufacturing to clinical centres testing the final application. The proposed innovations improve the global competitiveness of the European industry in the healthcare domain.

Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 6.65M | Year: 2015

Most older adults have multiple chronic diseases (multimorbidity) and multiple medications (polypharmacy). However, multimorbid patients are often excluded from clinical trials and most guidelines address diseases in isolation. Inappropriate drug prescription and poor drug compliance are common and contribute to up to 30% of hospital admissions. OPERAM investigators developed STOPP/START criteria to detect inappropriate drug use, both over- and underuse. Applying these criteria limits unnecessary polypharmacy and reduces underuse of indicated medications, but it remains uncertain whether systematic pharmacotherapy optimisation can improve clinical outcomes and reduce costs.We propose a multicentre randomised controlled trial to assess the impact of a userfriendly software-assisted intervention to optimise pharmacotherapy and to enhance compliance in 1900 multimorbid patients aged 75 years. Outcomes will include drug-related hospital admissions, health care utilisation, quality of life, patient preferences and cost-effectiveness. We will also perform several network meta-analyses (NMA) to provide new comparative evidence on the most effective and safest pharmacological and non-pharmacological interventions to reduce common causes of preventable hospital admissions (e.g. falls, fractures, bleeding). Therapy optimisation in the multimorbid elderly, enhanced compliance and discontinuation of less effective interventions have the potential to improve clinical, quality of life and safety outcomes, while reducing costs. We will provide a structured method with practical software solutions for optimal prescribing and new comparative evidence from NMAs for addressing multimorbidity and polypharmacy by means of customised, patient-centred guidelines. OPERAM ultimately aims at better healthcare delivery in primary and hospital care, based on effective, safe, personalised and cost-effective interventions that can be applied to the rapidly growing older population in Europe.

Cataldi A.,University of Chieti Pescara
Current Pharmaceutical Design | Year: 2010

Stress is a stimulus or a succession of stimuli tending to disrupt the homeostasis of an organism. An organism is consisting of a multitude of cells that singly undergo the effects of external factors that disturb or upset their homeostatic regulation. Stimuli acting as potential stressors are numerous, and include physical agents (ionizing radiation), non-physiological oxygen levels (hypoxia, hyperoxia) and chemotherapeutics. Lastly, also senescence, a physiological process occurring in all organisms, can be considered as a potential stressor. The cell response to multiple oxidative stresses involves mitochondria, since these organelles represent the major source of Reactive Oxygen Species (ROS) that drive the occurrence of pathological conditions and ageing by activating specific signalling pathways. Nevertheless, under physiological conditions the cells are able to exert an antioxidant response which, controlling ROS/Reactive Nitrogen Species (RNS) homeostasis, is involved in mediating cell differentiation, proliferation and migration. Thus, this review focuses the attention to the role played by mitochondria in the physiological and non-physiological signalling responses of eukaryotic cells to some oxidative stresses, in order to identify potential therapeutic targets to counteract oxidative stress effects and mitochondrial-related pathologies. © 2010 Bentham Science Publishers Ltd.

Coletti C.,University of Chieti Pescara
Accounts of chemical research | Year: 2012

Transition metal complexes containing unsaturated carbenes have enjoyed a recent surge in research interest. In addition to showing potential as molecular wires and as components of opto-electronic materials, they provide multifaceted reactive sites for organic synthesis. In this Account, we describe results of recent theoretical studies that delineate the main features of electronic structure and bonding in allenylidenes and higher cumulenylidene complexes, [L(m)M]{box drawing double horizontal}C({box drawing double horizontal}C)(n){box drawing double horizontal}CR(1)R(2) (where L represents the ligand, M the metal, and n ≥ 1). Although free cumulenylidene ligands, :C({box drawing double horizontal}C)(n){box drawing double horizontal}CR(1)R(2), are extremely unstable and reactive species, they can be stabilized by coordination to a transition metal. The σ-donation of the electron lone pair on the terminal carbon atom to an empty metal d-orbital, together with the simultaneous π back-donation from filled metal d(π)-orbitals to empty cumulene π* system orbitals, leads to the formation of a strong M{box drawing double horizontal}C bond with multiple character. Density functional theory studies on the model systems [(CO)(5)Cr({box drawing double horizontal}C)(n)CH(2)] and [trans-Cl(PH(3))(4)Ru({box drawing double horizontal}C)(n)CH(2)](+) (where n = 1-9) have been useful in interpreting the structural and spectroscopic properties and the reactivity of this class of complexes. Geometry optimizations significantly contributed to the generalization of the sparse structural data available for allenylidene, butatrienylidene, and pentatetraenylidene complexes to higher cumulenylidene complexes (with up to eight carbon atoms in the chain), which show a clear structural trend. In particular, the geometries of all even-chain cumulenes are consistent with an almost purely cumulenic structure, whereas the geometries of odd-chain cumulenes present a significant polyyne-like carbon-carbon bond length alternation. The calculated bond dissociation energies (BDEs) of the cumulenylidene ligand remain almost constant on lengthening the cumulene chain. These BDEs indicate that there is no thermodynamic upper limit to the cumulene chain length and suggest that the synthetic difficulties in preparing higher cumulenylidenes are due to an increase in reactivity. The calculated charges on the carbon atoms show no significant polarization along the cumulene chain, indicating that charge distribution is not important in determining the regioselectivity of either electrophilic or nucleophilic attack, which is instead determined by frontier orbital factors. The breakdown of the contributions from the metal and the carbon atoms along the chain to the HOMO and LUMO shows that the HOMO has contributions mainly from the metal and the carbon atoms in even positions along the chain (C(2), C(4), C(6), and higher). In contrast, the LUMO has contributions mainly from the carbon atoms in odd positions along the chain (C(1), C(3), C(5), and higher), thus explaining the experimentally observed regioselectivity of electrophilic and nucleophilic attacks, which are directed, respectively, to even and odd positions of the cumulenylidene chain. The study of the electronic structure of cumulenylidenes has allowed us not only to give a consistent rationale for the main structural and spectroscopic properties and for the reactivity of this emerging class of compounds but also to predict the effect of ancillary ligands on the metal center or substituents on the carbon end. The result is a useful guide to new developments in the still-underexplored fields of this fascinating class of compounds.

Mouthpiece of diving regulator of aqualung and/ or snorkel comprising a tubular connection portion (2) wherein said tubular connection portion has a through hole (3) internally engaged at a distal portion (4) with a complementary tubular portion of said aqualung and/ or snorkel to allow the air passage; and a bite (5) connected to said tubular connection portion at the lower edge (6) of the proximal end (7) extending complete arch acting as a support for a dental arch.

University of Chieti Pescara | Date: 2016-08-31

An enantio-selective process for the preparation of unnatural aromatic amino acids with restricted structure using non-chiral catalysts from natural amino acid and alkyl esters is disclosed.

Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC5-11d-2015 | Award Amount: 5.40M | Year: 2016

Five of the 20 raw materials identified by the European Commission as critical are commonly found in association with alkaline rocks and carbonatites (heavy and light rare earth elements, niobium, fluorspar, and phosphate). Other elements increasingly important for hi-tech applications, and found in these rocks include hafnium (Hf), tantalum (Ta), scandium (Sc) and zirconium (Zr). In fact, there is a greater chance of a carbonatite complex having resources economic to mine than any other rock type (about 20 active mines in ca. 500 known carbonatite complexes). Less than 3% of critical raw materials supply is indigenous to the EU. However, deposits are known and exploration is ongoing in parts of northern Europe. In central and southern Europe the presence of abundant alkaline volcanic rocks indicates the likelihood that deposits exist within about a km of the surface. This project will make a step-change in exploration models for alkaline and carbonatite provinces, using mineralogy, petrology, and geochemistry, and state-of-the-art interpretation of high resolution geophysics and downhole measurement tools, to make robust predictions about mineral prospectivity at depth. This will be achieved through studies at seven key natural laboratories, combined with Expert Council workshops. The results will be incorporated into new geomodels on multiple scales. In contrast to known deposits, Europe is well endowed with expertise. The project brings together industry partners involved in exploration, geophysics and environmental assessment with two geological surveys, a major museum and five universities. The results will make Europe the world leader in this specialist area. They will give the four SME industry partners world-leading expertise to develop and expand their businesses, transferring their business expertise from Africa to Europe. The project will help give European hi-tech industry the confidence to innovate in manufacturing using critical raw materials.

Agency: European Commission | Branch: H2020 | Program: COFUND-PCP | Phase: PHC-27-2015 | Award Amount: 5.19M | Year: 2016

MAGIC Post Stroke Project Team has united members from across Europe, dedicated to enable significant change in the delivery of health & social care (H&SC) services for patients post stroke. The consortium has recognised a significant gap in care associated with the recovery of such patients & we need a new way of meeting the needs of 508,000 new post stroke EU citizens/ year. Demographic changes are such that H&SC systems are failing to keep pace with demand & are not fit for purpose. By working in new ways & by reengineering systems with novel innovative technology & solutions we can think differently about our approach to care & improve the well-being for our patients; optimising the opportunity for recovery post stroke. Presently 1/3rd of all stroke patients are discharged from hospital with a significant change to life style, well-being, health status & independence. Community H&SC services do not enable patients to make a sufficient recovery post stroke. A search of state of the art technologies indicated much progress in the development of technologies to assist patients but no system is available to significantly affect rehabilitative improvement to scale; with no solution integration with H&SC services. Therefore, Public Procurers cannot go to open tender to deploy effective technology to solve system failures. The MAGIC Consortium recognised Pre-Commercial Procurement (PCP) as the only way to stimulate the market to find a solution to our common problem. MAGIC is an essential & strategically critical programme for the Team to optimise a patients recovery, to modernise H&SC systems to meet demand & to stimulate research, development & innovation. MAGIC will also stimulate European industry to become a global leader in this innovative field. Use of PCP is of particular interest to the consortium members & is new for many. Therefore, observer states will participate to contribute to the Pan-European improvement in care and to proactively share PCP knowledge.

Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-1-2014 | Award Amount: 4.00M | Year: 2016

By combining accurate magnetic measurements of neural activity with near-simultaneous high-definition measurements of cerebral structure provided by novel methods in ultra-low-field magnetic resonance imaging (ULF MRI ) we will be able to image the dynamics of human brain function at unprecedented resolution and reliability. BREAKBEN will achieve a revolution in neuroimaging; we aim at breaking the barrier for measurement of neuronal currents by ULF MRI (neural current imaging; NCI) as well as breaking the nonuniqueness barrier for magnetoencephalography (MEG) by combining it with ULF MRI and accurately presented a priori information. A key aspect in utilizing the a priori information is injected current density imaging (CDI), which will inform us about the individual conductivity structure of the head. Using novel verification and validation approaches, we will demonstrate the unique advantages of these multimodal techniques. These breakthroughs will result in completely different workflows in brain imaging, also suitable for clinical use. We believe that we are at the edge of a qualitative technology jump with ULF MRI, its applications and combinations. This will lead to a wealth of new applications and revolutionize the way we do magnetism-based measurements of the nervous system. Europe has the unique chance to lead this revolution.

Loading University of Chieti Pescara collaborators
Loading University of Chieti Pescara collaborators